IMNM (Immunome) Moat Score: 2/10 (As of Jul. 01, 2026)


IMNM Immunome Inc IMNM
44 GF Score
Price $21.39
GF Value $2.01
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Immunome Moat Score?

Immunome IMNM +0.94% 44 Moat Score is 2 as of Jul. 01, 2026. GuruFocus rates IMNM with a GF Score™ of 44/100 and a GF Value™ of $2.01 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,400 Biotechnology companies, Immunome ranks better than 58.07% on this metric.

Immunome has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Immunome has No Moat: Immunome Inc has limited market leadership and lacks significant customer switching costs or strong brand loyalty. The company operates in a competitive biotech sector with minimal durable cost advantages or regulatory barriers. Its intellectual property is not yet proven to provide a sustainable competitive edge.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Immunome might have No Moat - Very weak/transient advantages.

Immunome  (NAS:IMNM) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Immunome Moat Score Related Terms

IMNM vs AGIO, ABCL, KOD: Moat Score Comparison

For the Biotechnology subindustry, Immunome's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunome Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunome's Moat Score distribution charts can be found below:

* The bar in red indicates where Immunome's Moat Score falls into.


IMNM
44GF Score
Immunome Inc IMNM
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Immunome (IMNM) has a Moat Score of 2 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Immunome ranks #587 out of 1400 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Immunome's Moat Score too high?
Immunome's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Immunome's value of 2 is 0% at this industry median. Based on the distribution chart, Immunome ranks #587 out of 1400 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Immunome has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immunome's Moat Score compare to AGIO and ABCL?
According to the Biotechnology industry distribution chart, Immunome ranks #587 out of 1400 companies for Moat Score. This puts Immunome in the upper half of its industry. The industry median Moat Score is 2.00. Immunome's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immunome's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunome's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunome stock overvalued right now?
Based on GuruFocus' analysis, Immunome (IMNM) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.01, compared to a current price of $21.39 — trading 964.2% above its estimated fair value. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Immunome's overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Immunome (IMNM), the current Moat Score is 2 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immunome (IMNM) Overvalued in 2026?

Based on GuruFocus' analysis, Immunome stock appears to be overvalued. The current stock price of $21.39 is trading 964.2% above its estimated GF Value™ of $2.01. GuruFocus considers Immunome to be Significantly Overvalued.

Key valuation signals for IMNM:

  • Moat Score: 2
  • GF Value™: $2.01 vs. price of $21.39 (964.2% above fair value)
  • GF Score™: 44/100 with 1 warning sign
  • Industry Position: 0% at the Biotechnology median (#587 of 1400)

No single metric tells the full story. See the IMNM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunome Business Description

Address 18702 N. Creek Parkway, Suite 100, Bothell, WA, USA, 98011
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
44GF Score

Get the complete analysis for IMNM

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.39
Price
$2.01
GF Value